176961-53-8

Basic information

• Product Name: 2-(4-BROMO-PHENYL)-1H-IMIDAZOLE
• Synonyms: 2-(4-BROMO-PHENYL)-1H-IMIDAZOLE;1H-IMidazole,2-(4-broMophenyl)-;2-(4-BroMophenyl)iMidazole
• CAS NO: 176961-53-8
• Molecular Formula: C₉H₇BrN₂
• Molecular Weight: 223.07
• EINECS: 200-002-4
• Mol File: 176961-53-8.mol

Chemical Properties

• Boiling Point: 383.41 °C at 760 mmHg
• Flash Point: 185.68 °C
• Appearance: /
• Density: 1.566 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.636
• CAS DataBase Reference: 2-(4-BROMO-PHENYL)-1H-IMIDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-BROMO-PHENYL)-1H-IMIDAZOLE(176961-53-8)
• EPA Substance Registry System: 2-(4-BROMO-PHENYL)-1H-IMIDAZOLE(176961-53-8)

Safety Data

• Hazardous Substances Data: 176961-53-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical and Medicinal Research:
2-(4-BROMO-PHENYL)-1H-IMIDAZOLE is utilized as a key intermediate in the synthesis of various pharmaceutical compounds due to its anti-fungal, anti-bacterial, and anti-inflammatory properties. It aids in the development of new drugs targeting a range of diseases and conditions.
Used in Organic Synthesis:
In the field of organic synthesis, 2-(4-BROMO-PHENYL)-1H-IMIDAZOLE is employed as a versatile building block for the creation of more complex organic molecules. The presence of the bromine substituent allows for further functionalization and modification of the molecule, facilitating its use in the synthesis of a variety of organic compounds.
Used in Chemical Reactions:
2-(4-BROMO-PHENYL)-1H-IMIDAZOLE is also used as a reagent in various chemical reactions, taking advantage of its reactive bromine atom. This allows for the formation of new chemical bonds and the synthesis of novel compounds with potential applications in different industries.
Used in Drug Discovery:
2-(4-BROMO-PHENYL)-1H-IMIDAZOLE is employed as a valuable tool in drug discovery, where its unique structure and properties can be leveraged to identify and optimize potential therapeutic agents. Its presence in biologically active molecules can contribute to the development of new treatments for various diseases.

InChI:InChI=1/C9H7BrN2/c10-8-3-1-7(2-4-8)9-11-5-6-12-9/h1-6H,(H,11,12)

Upstream product

• 206535-83-3 2-(4-bromophenyl)-4,5-dihydro-1H-imidazole 
• 1122-91-4 4-bromo-benzaldehyde 
• 107-15-3 ethylenediamine 
• 586-75-4 4-chlorobenzoyl chloride 
• 288-32-4 1H-imidazole 
• 106-40-1 4-bromo-aniline 
• 623-00-7 4-bromobenzenecarbonitrile 
• 22483-09-6 2,2-dimethoxyethylamine 
• 131543-46-9 Glyoxal 

Downstream Products

• 1021919-39-0 2-(4-(trimethylstannyl)phenyl)-1H-imidazole 
• 1229584-17-1 2-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-1H-imidazole 
• 1256956-07-6 isobutyl 2-(4-bromophenyl)-1H-imidazole-1-carboxylate 
• 934744-50-0 2-(4-bromophenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole 
• 1269646-23-2 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole 
• 1269646-25-4 (S)-4-isopropyl-3-(3-(4-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-2-yl)phenyl)pyrazolo[1,5-a]pyrimidin-5-yl)oxazolidin-2-one 
• 1269643-37-9 (S)-3-(3-(4-(1H-imidazol-2-yl)phenyl)pyrazolo[1,5-a]pyrimidin-5-yl)-4-isopropyloxazolidin-2-one 
• 1269643-42-6 (S)-3-(3-(4-(1H-imidazol-2-yl)phenyl)pyrazolo[1,5-a]pyrimidin-5-yl)-4-phenyloxazolidin-2-one 
• 1332526-28-9 2-(4-bromophenyl)-1-(phenylsulfonyl)-1H-imidazole 
• 1021916-67-5 6-(4-(1H-imidazol-2-yl)phenyl)-1-(cyclohexylmethyl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one 
• 1229583-68-9 3-[4-(1H-imidazol-2-yl)-phenyl]-5-(3,4,5-trimethoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine 
• 1618658-98-2 4-(5-(4-(1H-imidazol-2-yl)phenyl)-4-(cyclopentyloxy)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide 

Relevant articles and documents

A sustainable approach towards the three-component synthesis of unsubstituted 1H-imidazoles in the water at ambient conditions

A green protocol for the synthesis of unsubstituted imidazoles has been demonstrated herein. The reaction is realized using commercially available lipase enzyme, porcine pancreas lipase (PPL) in water. The reaction conditions are selective and mild which helped to tolerate a wide variety of functional groups to give the desired products in good chemical yields. (Figure presented.).

Rh-Catalyzed Annulation of ortho-C?H Bonds of 2-Arylimidazoles with 1,4,2-Dioxazol-5-ones toward 5-Arylimidazo[1,2-c]quinazolines

A Rh-catalyzed unique and direct approach for constructing a series of 5-arylimidazo[1,2-c]quinazolines in moderate to excellent yields from simple and readily available 2-arylimidazoles and 3-phenyl-1,4,2-dioxazol-5-ones was described. This procedure pro

PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF

Provided herein are compounds and compositions useful in increasing PPARδ activity. The compounds and compositions provided herein are useful for the treatment of PPARδ related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).

As opioid receptor antagonists or inverse agonists of the novel compounds

Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.

PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF

Provided herein are compounds of Formula (I) and compositions useful in increasing PPARS activity. The compounds and compositions provided herein are useful for the treatment of PPARS related diseases (e.g., muscular diseases, vascular disease, demyelinat

Fe3O4/SiO2/(CH2)3N+Me3Br3- core-shell nanoparticles: A novel catalyst for the solvent-free synthesis of five- and six-membered heterocycles

Functionalized magnetic core-shell nanoparticles [Fe3O4/SiO2/(CH2)3N+Me3Br3-] are prepared by co-precipitation method, characterized by transmission electron microscopy, FT-IR, X-ray diffraction, and vibrating sample magnetometer. The catalytic activity of these nanoparticles was tested in the syntheses of imidazole, benzothiazole, and perimidine derivatives, under solvent-free conditions. The catalyst was readily recycled by the use of an external magnetic field and could be reused five times without significant loss of activity or mass.

COMPOUNDS FOR TREATMENT OF CANCER

The present invention relates to pharmaceutical compositions for treating cancer comprising BRAF inhibitors, (e.g. vemurafenib) and/or MEK inhibitor, (e.g. trametinib, RO5068760), in combination with anti-tubulin compounds of the invention or other known tubulin inhibitors, and using such compositions for treating cancer such as melanoma, drug-resistant cancer, and cancer metastasis.

An efficient and convenient synthesis of imidazolines and benzimidazoles via oxidation of carbon-nitrogen bond in water media

The metal coordination complex K4[Fe(CN)6] is an efficient and environmentally benign catalyst for the synthesis of imidazolines and benzimidazoles from various aldehydes and 1,2-diamines in aqueous medium at room temperature. This protocol gives excellent yield of product with desired purity. Copyright

Synthesis and antiproliferative activity of novel 2-aryl-4-benzoyl- imidazole derivatives targeting tubulin polymerization

We previously reported the discovery of 2-aryl-4-benzoyl-imidazoles (ABI-I) as potent antiproliferative agents for melanoma. To further understand the structural requirements for the potency of ABI analogs, gain insight in the structure-activity relationships (SAR), and investigate metabolic stability for these compounds, we report extensive SAR studies on the ABI-I scaffold. Compared with the previous set of ABI-I analogs, the newly synthesized ABI-II analogs have lower potency in general, but some of the new analogs have comparable potency to the most active compounds in the previous set when tested in two melanoma and four prostate cancer cell lines. These SAR studies indicated that the antiproliferative activity was very sensitive to subtle changes in the ligand. Tested compounds 3ab and 8a are equally active against highly paclitaxel resistant cancer cell lines and their parental cell lines, indicating that drugs developed based on ABI-I analogs may have therapeutic advantages over paclitaxel in treating resistant tumors. Metabolic stability studies of compound 3ab revealed that N-methyl imidazole failed to extend stability as literature reported because de-methylation was found as the major metabolic pathway in rat and mouse liver microsomes. However, this sheds light on the possibility for many modifications on imidazole ring for further lead optimization since the modification on imidazole, such as compound 3ab, did not impact the potency.

COMPOUNDS FOR TREATMENT OF CANCER

The present invention relates to novel compounds having anti-cancer activity, methods of making these compounds, and their use for treating cancer and drug-resistant tumors, e.g. melanoma, metastatic melanoma, drug resistant melanoma, prostate cancer and drug resistant prostate cancer.